Akers Biosciences (AKER) Reports FY17 Revenue of $3.93M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Akers Biosciences Reports Earnings for Fiscal Year 2017
April 3, 2018 7:04 AM EDTTotal Revenue Up 33%
THOROFARE, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (Akers, Akers Bio or the "Company"), a developer of rapid health information technologies, reports its financial results for the fiscal year ended December 31, 2017.
2017 Financial Highlights:
Total revenue up 33% to $3,929,527 (2016: $2,960,912)PIFA Heparin/PF4 Rapid Assay products continue to account for the majority of revenues however, growth was driven primarily by BreathScan Alcohol Breathalyzers, BreathScan OxiChek and the re-introduced Tri-Cholesterol testTotal revenue up across all... More